Neuroendocrine tumors (NETs) are rare cancers found in only about 2% of all individuals diagnosed with cancer each year. There are many varieties, with carcinoid being the most common one. NETs often release certain hormone-like substances into the bloodstream. Most cancers cause symptoms only in the organs they start in or spread to but carcinoid can cause symptoms throughout the body. NETs may appear almost anywhere, but they are most often found in the abdominal region, pancreas and lungs. Because symptoms resemble those of other diseases, such as irritable bowel syndrome and Crohn’s disease, they are often misdiagnosed for years. However, advances in treatment have improved the length of survival in carcinoids and other NETs.
The first type of Peptide Receptor Radionuclide Therapy (PRRT) approved by the U.S. FDA and the European EMA is Lutathera® (177Lutetium 177Lu-DOTATATE).
Sources: Norcalcarcinet.org, UCLAhealth.org
(Courtesy of Prof. Dr. Richard P. Baum, Zentralklinik Bad Berka, Germany) Cure of liver metastases from neuroendocrine pancreatic cancer using intra-arterial peptide receptor radionuclide therapy (PRRNT) shown here before treatment (on the left), one year after application of three cycles of Yttrium-90 somatostatin analogue (middle) and more than 5 years after the first image following the administration of an additional single systemic course of Lutetium-177 somatostatin analogue.
Europe: NET & MEN kanker vzw (BEL), Talk Blue Flanders (BEL), Lungeforeningen (DNK), Netzwerk Neuroendokrine Tumoren (NeT) e.V. (DEU), LuCE (CHE), Sarcoma Patients EuroNet (EU), Pancreatic Cancer Europe Network (EU), Selbsthilfegruppe Pankreaskarzinom (AUT)
Compassionate Use Program (CUP)
CUP enables patients with life-threatening diseases, such as advanced cancer, to resort to experimental treatments when standard anti-cancer solutions and access to clinical trials are not an option. Access to CUP programs depends on local regulations and can vary from one treatment to another.
Ask your referring physicians for more information regarding CUP.